Trever Bivona

Trever is a professor at the University of California, San Francisco, and a medical oncologist with a Ph.D. in cell and molecular biology. He maintains an active academic clinical practice and leads a basic and translational research laboratory focused on cancer genetics, precision medicine, and the molecular basis of targeted therapy response and resistance. Trever’s research has led to the discovery of several mechanisms of resistance to EGFR-targeted therapy, BRAF- and MEK-targeted therapy, and ALK-targeted therapy in lung and other cancers.

Trever is the recipient of numerous awards including the NIH Director’s New Innovator Award, the Pew-Stewert Scholar Award, and the Searle Scholars Award, the Doris Duke Clinical Scientist Development Award, and is an elected member of the American Society for Clinical Investigation.

Trever attended the New York University School of Medicine where he received his M.D. and Ph.D.